Endogenous progesterone and progestins in physiological pregnancy, in prevention and treatment of its complications

Authors

  • В. Ф. Нагорная Odessa National Medical University, Ukraine

DOI:

https://doi.org/10.18370/2309-4117.2013.13.30-44

Keywords:

pregnancy, miscarriage, progesterone, dydrogesterone

Abstract

Progesterone has the main role in the mechanisms of successful pregnancy. In obstetric practice to support the pregnancy with a deficit of progesterone progestins (progesterone analogues) are used. In obstetric practices in Ukraine progesterone, micronized progesterone, dydrogesterone are used. Analysis of long-term results of administration of progestogens during pregnancy, enduring the criteria of evidence-based medicine, was performed only for dydrogesterone. The main indication for the dydrogesterone use in obstetric practice is a treatment and prevention of miscarriages.

Author Biography

В. Ф. Нагорная, Odessa National Medical University

MD, Professor

References

  1. Salazar EL, Calzada L The role of progesterone in endometrial estradiol and progesterone-receptor synthesis in women with menstrual disorders and nabitual abortion. Gynecol. Endocrinol. 2007. № 23, (4). p. 222–225.
  2. Labeta MO, Margni RA, Leoni J, Binaghi RA Structure of asymmetric non-precipitating antibody. Immunology 1986; 57: 311–7.
  3. Fanchin R, Fridman R Human Chorionic gonadotropin: Does it affect human endometrial morphology in vivo? – Sem. Reproductive Med. – 2001. – V 19(1) – P. 31–35.
  4. Carp H A systematic review of dydrogesterone for the treatment of threatened miscarriage. Gyn. Endocr., 2012, Early Online: 1–8.
  5. Fillicori M et al. Neuroendocrine regulation of the corpus luteum in the human: evidence for pulsative progesterone secretion – J.Clin. Invest., 1984, 73,1638.
  6. La Marca A, Morgante G, De Leo V Human chorionic gonadotropin, thyroid function, and immunological indices in threatened abortion Obstet. Gynecol. 1998: 92: 206–211.
  7. Florio P, Luisi S, D’Antona D, Severi FM Rago G Petraglia F Maternal serum inhibin A levels may predict pregnancy outcome in women with threatened abortion. Fertil. Steril 2004: 81: 468–470.
  8. Schmidt T, Rein DT, Foth D, Eibach HW, Kurbacher CM, Mallmann P, Romer T Prognostic value of repeated serum CA 125 measurements in first trimester pregnancy. Eur J.Obstet. Gynecol. Reprod. Biol. 2001; 97;168–173.
  9. Fiegler P, Katz M, Kaminski K Rudol G Clinical value of a single serum CA-125 level in women with symptoms of imminent abortion during the first trimester of pregnancy. J. Reprod. Med. 2003; 48; 982–988.
  10. Szekeres – Bartho J, Kilar F, Falkay G et al. Progesterone – treated limphocytes of healthy pregnant women release, a factor inhibiting, cytotoxicity and prostaglandin synthesis. Am, J Reprod Immunol 1985; 9: 15–19.
  11. Szekeres – Bartho J, Barakonyi A, Par G, Polgar B, Palkovics T, Szeredayl Progesterone as an immunomodulatory molecule. Jnt. Immunopharmacol 2001; 1(6): 1037–1048.
  12. Schindler AE Jmmunology and progestins in pregnansy. Gynecol. Endocrinol 1999: 13 (Suhh l/4); 47–50.
  13. Schindler AE Endocrinology of pregnancy: consequences for the diagnosis and treatment of pregnancy disorders. J.Steroid Biochem Mol Biol; 2005; 97; 386–8.
  14. Bacg X, Saney T, Brechot MC et al. Intrahepatic cholestasis of pregnancy. Hepatology 1997; 26: 358–64.
  15. Nyberg S, Backstrom T, Zingmark E et al. Allopregnanolone decrease with symptom improvement during placebo and GnRG agonist treatment in women with severe premenstrual syndrome Gynerocol Endocrinol 2007.: 23: 257–266.
  16. Andreen L, Bixo M, Sundstom-Poromaa I et al. Progesterone effects during sequential H RT. Eur. J Endocrinol 2003; 148–571–7
  17. Andreen L, Sundstom-Poromaa J Bixo M et al. Relationship between allopregnanolone and negative mood in postmenopausal women taking sequential HRT with vaginal progesterone. Psychoneuroendocrinol 2005; 30: 212–24.
  18. Daya S Luteal support. Maturitas 2009; 65: 29–34.
  19. Working Group NHO, 1984. Сидельникова В.М., Сухих Г.Т. Невынашивание беременности: Руководство для практикующих врачей. – М.: ООН «Мед. инф.агенство» 2010. – 536 с.
  20. Schindler AE Differential effects of progestins. Maturitas 2003; 46; 83–5. Instructions for medical use of Duphaston from 14/12/2012.
  21. Arck PC, Rucke M, Rose M, Szekeres-Bartho J, Douglas AJ, Pritsch M, Blois SM et al. Early risk factors for miscarriage: a prospective cohort study in pregnant women. Reprod Biomed Online 2008; 17: 101–113.
  22. Maconochie N, Doyle P, Prior S, Simmons R Risk factors for first trimester misscarriage – results from a UK-population-based casecontrol study. BJOG 2007; 114: 170–186.
  23. Gracia CR, Sammel MD, Chittams J, Hummel AC, Shaunik A, Barnhart KT Risk factor for spontaneous abortion in early symptomatic first trimester pregnancies. Obstet Gynecol 2005; 106: 993–999.
  24. Achiron R, Tadmor O Mashiach S Heart rate as a predictor of first trimester spontaneous abortion after ultrasound proven viability. Obstet Gynecol 1991; 78: 330–334.
  25. Oates Whitehead RM,Haas, DM Carrier Jak Progesteron for preventing miscarriage (Review), 2007 The Cochrane Collaboration Published by John Wiley a Sons, Ltd
  26. Радзинский В.Е. Парадоксы привычного невынашивания беременности. Научные материалы Общероссийского научно-практического семинара
  27. Meis PJ Klebanoff M, Thom E et al. Prevention of recurrent preterm delivery by 17-alpha hydroxyprogesterone caproate. N. Engl. J. Med. 2003; 348–2379–85.
  28. Demirkiran M, Aslan K, Bicakci S, Bozdemir H, Ozeren A Trasient parkinsonism: induced by progesterone of pregnancy Mov. Disord 2004; 19: 1382–4.
  29. Lanzetta P, Crovato S, Pirracchio A, Bandello F Retinal arteriolar obstruction with progesterone treatment of threatened abortion. Acta Ophthalmol Scand 2002; 80: 667–8.
  30. Van Amsterdam PH, Overmans H, Scherpenisse PM et al. Dydrogesterone: Metabolism in man. Eur J.Drug Metab Pharmacokinet 1980; 5: 173–184.
  31. Сухих Г.Т., Громова О.А, Торшин И.Ю. и др. Невынашивание беременности. Молекулярные механизмы дидрогестерона (Дуфастон).
  32. Schindler AE, Campagnoli C, Druckmann R et al. Classification and pharmacology of progestins. Maturitas 2008; 61: 1–2: 171–180.
  33. Kalinka J, Radwan M The impact of dydrogesterone supplementation on serum cytokine profile in women with threatened abortion. Am J Reprod Jmmunol 2006; 55: 115–21.
  34. Simoncini T еt al. Effects of dydrogesterone and of its stable metabolite, 20α – dihydrogesterone, on nitric oxide synthesis in human endothelial cells. Fertility and Sterility. Vol.86 Suppl 3, October 2006, 1235–1242.
  35. Simoncini T Genazzani AR Raloxifen acutely stimulates nitric oxide release from human endothelial cells via an activation of endothelial nitric oxide synthase J Clin. Endocrinol Metab 2000; 85: 2966–9.
  36. Nagornaya V, Marichereda V Early prophylaxis of preeclampsia in women at rick for сhanges in spiral arteries. Cnina journal of Modern Medicine 1005-8982 (2011) 23–33. 35–06.
  37. EL-Zibdeh MY Yousef LT. Dydrogesterone support in threatened miscarriage. Naturitas 2009; 65 Suppl 1: 543–6.
  38. Chakravarty BN, Schirazee HH, Dam P Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology HRT cycles. J. Steroid. Biochem Molecul Biol 2005; 97(5): 416–30.
  39. Luteal phase support for assisted reproduction cycles (Review) Copyright (c) 2012 The Cochrane Collaboration Published by John Wiley. Soks, LTD (Van der Linden M, Buckingham V., Farguhar C., Kremer GAM., Metwally M.).
  40. Haas DM Ramsey P.S. Progesteron for preventing miscarriage. Cochrane Databasa Syst Rev 2008; (2): CD003511. 1.
  41. Swyer YL, Daley D Progesteron implantation in habitual abortion. Br. Med J 1953: 1: 1073–1077.
  42. Goldzieher JW Double-blind trial of a progestin in habitual abortion. YAMA 1964; 198: 651–654.
  43. Le Vine L Habitual abortion. A controlled study of progestational therapy. West J Syrg Obstet Gynecol 1964; 72: 30–36.
  44. Wahabi HA, Fayed AA Esmaeil SA, Al Zeidan RA Progesteron for treating threatened miscarriage. Cochrane Database of Systematic Reviews 2011, is sue 12 № 6 CD 005943. DOI:10.1002|14651858. CD 005943. pub.4.
  45. EL-Zibden MY Dydrogesterone in the reductin of recurrent spontaneous abortion. J Steroid Biochem Molecul Biol 2005; 97: 435–8.
  46. Pandian RU Dydrogesterone in threatened miscarriage: a Malaysian experience. Maturitas 2009; 65 Suppl S 47–50.
  47. Gerhard I, Gwinner B, Eggert-Kruse W, Runnebaum B Double blind controlled trial of progesterone substitution in threatened abortion. Biologicl Research in Pregnancy and Perinatology 1987; 8: 26–34.
  48. Palagiano A, Bulletti C, Pace MC et al. Effects of vaginal progesterone on pain and uterine contractility in patients with threatened abortion before twelve weeks of pregnancy. Annals of the New York Academy of Sciences 2004; 1034: 200–10.
  49. Van der Linden M, Buckingham K, Farguhar C, Kremer GAM, Metwally M Luteal phase support for assisted reproduction cycles (Review). Copurighto 2012 Nhe Cochrane Collaboration Published by john Wiley 8 Sons, Ltd. Cochrane review prepared and maintained by the Cochrane Collaboration and published in Cochrane Library 2012, issue 8.
  50. Rode L, K.Klein, KH Nicolaides, E Krampe-Bettelheim, A Tobor Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo-controlled trial on the effect of vaginal micronizead progesterone. Ultrasound Obstet Gynecol 2011: 38; 272–280.
  51. K. Klein, L.Rode et al. Vaginal micronized progesterone and risk preterm delivery in high-risk twin pregnancys; secondary analysis, of a placebo-controlled randomized trial and metaahalysis Ultrasound Obstet Gynecol 2011; 38: 281–287.
  52. Wanesh Ashalatha Nishant Chakravotry et al. Comparison of oral dydrogesterone with progesterone gel and micronized progesterone for luteal supprt in 1373 women undergoing in vitro fertilization: a randolomized clinical study. Fertil Streril 2011;95;1961–5.
  53. Oates-Whitehead RM, Haas DM, Carrier JAK Progesteron for preventing miscarriage (Review) 2007 The Cochrane Collaboration. The Cochrane Library 2007, issue 4.
  54. Suzar L, Carmichael et al. Maternal Progestin Intake and Risk of Hypospadias. Arch. Pediatr Adolesc Med. 2005; 159; 957–962.
  55. Sidelnikova VM, Sukhikh GT Miscarriage: Guidelines for practitioners. – Moscow: OOO «Medical Information Agency», 2010. – 536.
  56. Repina MA Didrogesteron-progesterone successful pregnancy // Gynecology. – 2001. – № 2, T. 13. – P. 25–35.
  57. Nikolov NS, Enchev EM, Genev PV, Documov SI, Vyrbanov VG Laboratory, functional and radiological diagnostics in obstetrics and gynecology. – Sofia: «Health and Physical Education», 1964. – 428 p.
  58. Milku Sht-M, Muster AD Gynecological endocrinology. – Ed. ASRR, 1973. – 484 p.
  59. Schindler A Progestogen effects of dydrogesterone // Women’s Health. – 2011. – № 3 (59). – P. 138–144.
  60. Silber AP, Schiffman MN Obstetrics by anesthesiologist view. «Etudes of critical medicine», Vol. 3. – Petrozavodsk: PGU, 1997. – 397 p.
  61. Klyhunenko AN, Volkov AA, Vetoshka IA, Lutsenko VV Effect of pregnancy on cognitive function. Pain, pain relief and intensive therapy. – 2013. – № 1 D. – P. 70–73.
  62. Magdik IV Duphaston in obstetrics and gynecology practice. Medical liability // Health of Ukraine. – 2012. – № 2 (6). – P. 5.
  63. Radzinsky VE Paradoxes of recurrent miscarriage. All-Russian Scientific Research materials and practical seminar «The reproductive potential of Russia: Siberian reading» (Novosibirsk, 2012) // Status Praesens. – 2012.
  64. Instructions for medical use of Utrogestan from 27.11.2008.
  65. Progesterone Compendium «Drugs.» – 2006. – Volume 1, L-1145, P. 242.a.
  66. Sukhikh GT, Gromova OA, Torshin IY et al. Miscarriages. Molecular mechanisms of dydrogesterone (Duphaston). Genome-wide study of transcriptional effects of progesterone, androgen and estrogen receptors. // Problems of reproduction. – 2010.
  67. Sukhikh GT, Torshin IY, Gromova OA, Yurhel IS, Galditskaya SA Molecular mechanisms of dydrogesterone (Duphaston). Part 1. Study of the selectivity of the interaction of dydrogesterone with progesterone receptors by molecular mechanics // Problems of reproduction. – 2010.
  68. Marichereda VG Preeclampsіa: immunogenetic determinants of of pathogenesis, diagnosis and prognosis. – Author. diss. ... Odessa, 2013.
  69. Podolsky VV et al. Prevention preeclampsia by correcting of progesterone deficiency in the first trimester. – Newsletter, Kyiv, 2011.
  70. Pelinesku-Onchul Dimitriya Dydrogesterone in the treatment of subhorial hematoma // Gynecology. – 2008. – Vol.10, № 2.
  71. Gladkova KA, Menzhinsky IV, Sukhikh GT, Sidelnikova VM Role of sensitization to progesterone in recurrent miscarriage clinic // Problems of reproduction. – 2007. – P. 95–98.
  72. Kuznetsova IV, Geppe NA, Grigoryan AN Hormone therapy during pregnancy and its effects on the offspring // Questions of Practical Pediatrics. – 2012. – T. 7, № 3. – P. 45–49.

Downloads

Published

2013-11-17

How to Cite

Нагорная, В. Ф. (2013). Endogenous progesterone and progestins in physiological pregnancy, in prevention and treatment of its complications. REPRODUCTIVE ENDOCRINOLOGY, (13), 30–44. https://doi.org/10.18370/2309-4117.2013.13.30-44

Issue

No. 13 (2013)

Section

Pregnancy and childbirth

License

Copyright (c) 2014 В. Ф. Нагорная

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.